Breaking

US Venture Capital Fades in China While Dealmakers Hunt for AI Advantage

September 23, 2026 at 20:30 EDT

Foundation Models
Funding & M&A
Policy & Regulation

U.S. venture capital investments in Chinese companies have plummeted 80 percent from their 2021 peak, with foreign capital in China's venture market shrinking to just $3.7 billion in 2023—one-tenth the height of pre-decline levels. Yet American VCs continue to travel to China on reconnaissance missions, drawn by the rapid ascent of competitive Chinese AI labs that are challenging Silicon Valley's technological dominance.

AI Venture Capital

U.S. VC in China Down 80%, But Dealmakers Study AI

American venture investors have dramatically reduced capital to Chinese startups over five years, yet continue research trips to understand China's competitive AI labs and technological advances.

80%

Decline in U.S. venture deals to China from 2021 peak

$3.7B

Foreign investment in Chinese VC in 2023 (10% of 2021)

15.5×

U.S. AI VC funding lead vs. China (Q1 2026)

Near-zero

AI benchmark gap between China and U.S. labs

Why U.S. VCs Still Visit Despite Capital Pullback

Chinese AI labs (DeepSeek, Zhipu, MiniMax) achieving competitive performance benchmarks despite dramatically lower funding
Hong Kong IPO exits emerging (MiniMax doubled on debut; Zhipu raised $6.5 billion), creating new visibility
Recent visits by Founders Fund, Khosla Ventures, and Thrive Capital signal renewed interest in market intelligence
Regulatory environment allows research and fact-finding trips while formal investment remains restricted by CFIUS and export controls

Key insight: Despite 80% capital decline, understanding China's AI capabilities has become strategically necessary for U.S. VCs, even if direct funding faces regulatory barriers.

Continue reading

The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.